Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2025 | $53.00 | Outperform | Mizuho |
| 12/17/2025 | $64.00 | Buy | Citigroup |
| 9/26/2025 | $43.00 | Buy | Deutsche Bank |
| 4/8/2025 | $45.00 | Outperform | Leerink Partners |
| 3/18/2025 | $27.00 | Outperform | Wolfe Research |
| 9/4/2024 | $45.00 | Outperform | Wedbush |
| 7/16/2024 | Outperform | Evercore ISI | |
| 5/2/2024 | $50.00 | Outperform | Robert W. Baird |
WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional $45.0 million of shares of common stock at the public offering price, less the underwrit
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 40% and endoscopic improvement of 51% SPY001 was well tolerated with a safety profile consistent with the α4β7 class Recruitment for SKYLINE Part A closed, now enrolling Part B monotherapy and combination cohorts Management will host a conference call today at 8:00 a.m. ET WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibo
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre'
424B5 - Spyre Therapeutics, Inc. (0001636282) (Filer)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)
Mizuho initiated coverage of Spyre Therapeutics with a rating of Outperform and set a new price target of $53.00
Citigroup initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $64.00
Deutsche Bank initiated coverage of Spyre Therapeutics with a rating of Buy and set a new price target of $43.00
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)
Continued execution towards expected milestones across portfolio, with SPY001 on-track for interim Phase 1 data by year-end 2024, and SPY002 on-track for initiation of first-in-human trials in the fourth quarter of 2024 Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold increase in non-human primate half-life compared to risankizumab Accelerated expected initiation of first-in-human trial for SPY003 to the first quarter of 2025 $414 million of cash, cash equivalents, and marketable securities as of September 30, 2024, with expected runway well into 2027, through multiple clini
WALTHAM, Mass., Oct. 1, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ:SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Sheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer. Dr. Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years
Initiated dosing in Phase 1 trial of SPY001, an anti-α4β7 antibody engineered for infrequent, subcutaneous maintenance dosing, with interim proof-of-concept data on track for year-end 2024 SPY002, an anti-TL1A antibody program designed for enhanced potency to both TL1A monomers and trimers, and extended half-life compared to existing molecules, remains on track to begin first-in-human trials in the second half of 2024 Nominated a development candidate for SPY003, a highly potent anti-IL-23 antibody with an extended half-life compared to existing molecules, with expectations to begin a first-in-human trial in the first half of 2025 $426 million of cash, cash equivalents, marketable securities
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score Secondary endpoints included clinical remission by modified Mayo Score of 40% and endoscopic improvement of 51% SPY001 was well tolerated with a safety profile consistent with the α4β7 class Recruitment for SKYLINE Part A closed, now enrolling Part B monotherapy and combination cohorts Management will host a conference call today at 8:00 a.m. ET WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibo
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results. To access the live and archived webcast, please visit the Investor Relations page of Spyre'
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more than 3-fold greater than first-generation anti-TL1A antibodies SKYLINE-UC platform study evaluating three optimized monotherapies and three potentially paradigm-changing combinations in ulcerative colitis, initiated in May 2025 SKYWAY-RD basket study evaluating SPY072 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) announced, with initiation expected in Q3 2025 Management to host a webcast and conference call today at 8:00 a.m. ET WALTHAM, Mass., June 1